Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy
Tóm tắt
Gastrointestinal stromal tumors (GISTs) are rare tumors of the wall of the stomach and small bowel, and also occasionally arise in the mesentery, omentum, or retroperitoneum. The incidence of GIST in the United States is approximately 500 to 750 patients per 100,000 people. GISTs often present late in their clinical course unless they are the cause of gastrointestinal bleeding or perforation. Surgical resection is the standard of care for primary GIST. However, there is a high risk of recurrence in the peritoneum and liver. For metastatic GIST, imatinib mesylate is the standard of care. Two phase III studies presented in 2003 in abstract form show slightly different results. In the US study, 400 mg/d was found to be equivalent to 800 mg/d with respect to response, progression-free survival, and overall survival at 12 months. In the European/Australasian study, the response rate was the same with either dosage, but progression-free survival was better with 800 mg/d compared with 400 mg/d. Overall survival data for the latter study were too immature for analysis as of May 2003. Adjuvant or neoadjuvant therapy with imatinib is the topic of at least three studies through the American College of Surgeons Oncology Group and Radiation Therapy Oncology Group and the American College of Radiology Imaging Network. Every effort to enroll eligible patients on these studies should be made. New treatments for metastatic disease under investigation include a tyrosine kinase inhibitor with an expanded panel of targets compared with imatinib (SU011248), and the addition of a mammalian target of rapamycin (mTOR) inhibitor and the rapamycin derivative RAD001 to imatinib. Given the finding of a specific molecular defect to exploit, GISTs have gone from an orphan disease to a proving ground for tyrosine kinase-targeted therapy.
Tài liệu tham khảo
Mazur MT, Clark HB: Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983, 7:507–519.
Chan JK: Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases? Adv Anatomy Pathol 1999, 6:19–40.
Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577–580.
Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M: CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998, 11:728–734.
Edmonson JH, Marks RS, Buckner JC, Mahoney MR: Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002, 20:605–612.
Eilber FC, Rosen G, Forscher C, et al.: Recurrent gastrointestinal stromal sarcomas. Surg Oncol 2000, 9:71–75.
Demetri GD: Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001, 28:19–26.
Heinrich MC, Corless CL, Duensing A, et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708–710. This paper is the first to describe a tyrosine kinase receptor pathway other than the KIT tyrosine kinase pathway that appears to be responsible for the generation of GISTs in a small percentage of patients with this diagnosis.
Judson I: Gastrointestinal stromal tumours (GIST): biology and treatment. Ann Oncol 2002, 13:287–289.
van Oosterom AT, Judson I, Verweij J, et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421–1423. The first phase I study of imatinib in patients with GIST showed that the majority of patients achieved partial responses.
Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472–480. This study of 140 patients confirmed the high response rate to imatinib seen in the phase I study.
Benjamin RS, Rankin C, Fletcher C, et al.: Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results [abstract]. Proc Am Soc Clin Oncol 2003, 22:3271. This represents the state of the art in GIST therapy. Two phase III studies prove the activity of imatinib at 400 mg/d and show response rates are identical at 400 or 800 mg/d. The analysis is preliminary, however.
Verweij J, Casali PG, Zalcberg J, et al.: Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG [abstract]. Proc Am Soc Clin Oncol 2003, 22:3272. The study was similar to the study by Benjamin et al. [12], but early results indicate that the higher dose (800 mg/d) is favorable with respect to progression-free survival. It is also unclear if overall survival will turn out to be different. With time, the picture will become clearer.
Demetri GD, George S, Heinrich MC, et al.: Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate [abstract]. Proc Am Soc Clin Oncol 2003, 22:3273. For those patients with progression on imatinib, SU11248 offers at least some evidence of activity in imatinib-refractory patients.